NSCLC is commonly treated by radiation, surgery and chemical therapy, but the approval of the antibodies targeting immune checkpoints PD-1 and ligand (PD-L1) had a big impact for the immunotherapy of this and other cancers. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.